Cargando…
Doripenem in hospital infections: a focus on nosocomial pneumonia, complicated intra-abdominal infections, and complicated urinary tract infections
Doripenem is the latest carbapenem on the market to date. Although not an antibiotic in a new class, it offers a glimmer of hope in combating serious infections secondary to multidrug-resistant Gram-negative bacteria when we have not seen a new class of antibacterial, particularly for Gram-negative...
Autores principales: | Lo, Tze Shien, Borchardt, Stephanie M, Welch, Justin M, Rohrich, Melissa A, Alonto, Augusto M, Alonto, Anne V |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3108726/ https://www.ncbi.nlm.nih.gov/pubmed/21694886 |
Ejemplares similares
-
Critical evaluation of ceftolozane–tazobactam for complicated urinary tract and intra-abdominal infections
por: Giancola, Stephanie E, et al.
Publicado: (2016) -
Analysis of patients with diabetes and complicated intra-abdominal infection or complicated urinary tract infection in phase 3 trials of ceftolozane/tazobactam
por: Popejoy, Myra W., et al.
Publicado: (2017) -
Powassan virus infection: case series and literature review from a single institution
por: Raval, Mihir, et al.
Publicado: (2012) -
Ceftazidime/avibactam: a novel cephalosporin/nonbeta-lactam beta-lactamase inhibitor for the treatment of complicated urinary tract infections and complicated intra-abdominal infections
por: Hidalgo, Jose A, et al.
Publicado: (2016) -
Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program
por: Wagenlehner, Florian M., et al.
Publicado: (2016)